Bridgebio Pharma Stock Today
| BBIO Stock | USD 33.75 1.56 4.85% |
PerformanceOK
| Odds Of DistressBelow Average
|
BridgeBio Pharma is selling at 33.75 as of the 19th of March 2025; that is 4.85 percent increase since the beginning of the trading day. The stock's open price was 32.19. BridgeBio Pharma has about a 37 percent probability of financial distress in the next few years of operation and did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 19th of December 2024 and ending today, the 19th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 27th of June 2019 | Category Healthcare | Classification Health Care |
BridgeBio Pharma, Inc. engages in the discovery, development, and delivery of various medicines for genetic diseases. The company was founded in 2015 and is headquartered in Palo Alto, California. Bridgebio Pharma operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. The company has 190.19 M outstanding shares of which 20.18 M shares are currently shorted by private and institutional investors with about 6.64 trading days to cover. More on BridgeBio Pharma
Moving against BridgeBio Stock
Follow Valuation Options Odds of Bankruptcy
Check how we calculate scores
BridgeBio Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Chairman Development | Richard Scheller | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Biotechnology, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsBridgeBio Pharma can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand BridgeBio Pharma's financial leverage. It provides some insight into what part of BridgeBio Pharma's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
BridgeBio Pharma (BBIO) is traded on NASDAQ Exchange in USA. It is located in 3160 Porter Drive, Palo Alto, CA, United States, 94304 and employs 725 people. BridgeBio Pharma is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Mid-Cap' category with a current market capitalization of 6.12 B. BridgeBio Pharma conducts business under Biotechnology sector and is part of Health Care industry. The entity has 190.19 M outstanding shares of which 20.18 M shares are currently shorted by private and institutional investors with about 6.64 trading days to cover.
BridgeBio Pharma currently holds about 715.71 M in cash with (520.73 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.83.
Check BridgeBio Pharma Probability Of Bankruptcy
Ownership AllocationBridgeBio Pharma holds a total of 190.19 Million outstanding shares. The majority of BridgeBio Pharma outstanding shares are owned by other corporate entities. These outside corporations are usually referred to as non-private investors looking to acquire positions in BridgeBio Pharma to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in BridgeBio Pharma. Please pay attention to any change in the institutional holdings of BridgeBio Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check BridgeBio Ownership Details
BridgeBio Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Alliancebernstein L.p. | 2024-12-31 | 2.8 M | |
| Woodline Partners Lp | 2024-12-31 | 2.2 M | |
| Goldman Sachs Group Inc | 2024-12-31 | 2 M | |
| Ensign Peak Advisors Inc | 2024-12-31 | 2 M | |
| Manufacturers Life Insurance Co | 2024-12-31 | 1.9 M | |
| Sc Us (ttgp), Ltd. | 2024-12-31 | 1.9 M | |
| Ubs Group Ag | 2024-12-31 | 1.8 M | |
| Pictet Asset Manangement Sa | 2024-12-31 | 1.8 M | |
| Fmr Inc | 2024-12-31 | 1.6 M | |
| Kohlberg Kravis Roberts & Co Lp | 2024-12-31 | 25.3 M | |
| Viking Global Investors Lp | 2024-12-31 | 25.1 M |
BridgeBio Pharma Historical Income Statement
BridgeBio Stock Against Markets
BridgeBio Pharma Corporate Management
| Neil Kumar | President, CoFounder | Profile | |
| MBA CPC | Chief Officer | Profile | |
| Maricel Apuli | Chief Officer | Profile | |
| Eli Wallace | Chief Oncology | Profile | |
| Uma Sinha | Chief Officer | Profile | |
| JD MD | Chief Therapy | Profile |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BridgeBio Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. To learn how to invest in BridgeBio Stock, please use our How to Invest in BridgeBio Pharma guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BridgeBio Pharma. If investors know BridgeBio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BridgeBio Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share | Quarterly Revenue Growth 2.371 | Return On Assets | Return On Equity |
The market value of BridgeBio Pharma is measured differently than its book value, which is the value of BridgeBio that is recorded on the company's balance sheet. Investors also form their own opinion of BridgeBio Pharma's value that differs from its market value or its book value, called intrinsic value, which is BridgeBio Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BridgeBio Pharma's market value can be influenced by many factors that don't directly affect BridgeBio Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BridgeBio Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if BridgeBio Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BridgeBio Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.